Thursday, May 9, 2024

Ads by Google

Ads by Google

GUJCET 2024 results releasing tomorrow at 9AM: Here’s the official notice

GUJCET Result date 2024: The Gujarat Secondary and Higher Secondary Education Board, Gandhinagar will be declaring the Gujarat Common Entrance Test (GUJCET) 2024 result...
HomeBusinessEris to acquire branded formulations of Biocon subsidiary for Rs 1242 crore

Eris to acquire branded formulations of Biocon subsidiary for Rs 1242 crore

Biocon Biologics

is selling its branded formulations business to Mumbai-based

Eris Lifesciences

for Rs 1242 crore.
With the deal, Eris will jumpstart its entry into the Rs 30,000+ crore

injectables market

in India, and acquire two major insulin brands – Basalog and Insugen.
This acquisition will also mark Eris’ entry into oncology and critical care, says a company statement.

Under this deal, it has also signed a 10-year

supply agreement

with the

Biocon subsidiary

. The Biocon product range will continue to be manufactured and supplied to Eris for commercialization in India.

This acquisition also provides immediate synergies with the recently acquired Swiss Parenterals business, it adds.
The Biocon product range can be quickly scaled up by leveraging the product portfolio of Swiss, which consists of 240+ unique molecules. The combination of the two deals also provides margin expansion opportunities through insourcing/ technology transfer of manufacturing to Swiss’ facilities.